Epidemiology and clinical impact of major comorbidities in patients with COPD

Abstract

Comorbidities are frequent in chronic obstructive pulmonary disease (COPD) and significantly impact on patients' quality of life, exacerbation frequency, and survival. There is increasing evidence that certain diseases occur in greater frequency amongst patients with COPD than in the general population, and that these comorbidities significantly impact on patient outcomes. Although the mechanisms are yet to be defined, many comorbidities likely result from the chronic inflammatory state that is present in COPD. Common problems in the clinical management of COPD include recognizing new comorbidities, determining the impact of comorbidities on patient symptoms, the concurrent treatment of COPD and comorbidities, and accurate prognostication. The majority of comorbidities in COPD should be treated according to usual practice, and specific COPD management is infrequently altered by the presence of comorbidities. Unfortunately, comorbidities are often under-recognized and under-treated. This review focuses on the epidemiology of ten major comorbidities in patients with COPD. Further, we emphasize the clinical impact upon prognosis and management considerations. This review will highlight the importance of comorbidity identification and management in the practice of caring for patients with COPD.

Depression, anxiety and chronic pain in patients with chronic obstructive pulmonary disease: the influence of breath

“…Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by chronic inflammation and dysfunction of the upper airways [1,2]. The WHO estimates a current mortality rate of around 64 million people; it has been estimated that, in 2030, COPD will represent the third cause of mortality in the world [1].…”

“…The WHO estimates a current mortality rate of around 64 million people; it has been estimated that, in 2030, COPD will represent the third cause of mortality in the world [1]. Currently, the relation between comorbidities and the presence and evolution of COPD is still unclear [2]. Comorbidities such as depression, anxiety and chronic pain are commonly observed [3].…”

Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease: A Review for Definition, Epidemiology, Pathology, and Diagnosis

“…Hilde et al reported the prevalence of PHT as 5%, 27% and 53% for COPD stage II, III and IV, respectively. On the other hand, about 17% of patients with PHT were reported to have COPD [6,19].…”

“…The main goal of lifestyle changes according to clinical and functional status, training, drug therapy, pulmonary rehabilitation, long-term oxygen therapy, noninvasive mechanical ventilation and bronchoscopic/surgical interventions is to reduce the symptoms and future risks [1,4]. Pulmonary hypertension (PHT) which is a common complication of COPD, is determinant for the prognosis of COPD, and is estimated to be the leading fourth cause of death by 2030 [5,6].…”

Outcomes of Percutaneous Coronary Intervention in St Elevation Myocardial Infarction and Chronic Obstructive Pulmonary Disease

“…В последние годы значительно возросло число публикаций, оценивающих клинические исходы коморбидной патологии -ишемической болезни сердца (ИБС) и хронической обструктивной болезни легких (ХОБЛ) [1][2][3][4][5], имеются указания об ассоциа-ции ХОБЛ с увеличением риска смертности от сер-дечно-сосудистых причин при выполнении аорто-коронарного шунтирования (АКШ) [6,7]. В то же время остается небольшим число исследований, оценивающих эффективность и исходы чрескож-ного коронарного вмешательства (ЧКВ) у пациен-тов с сопутствующей ХОБЛ в сравнении с общей популяцией.…”